A significant proportion (almost one-third) of smokers with ischemic heart disease have undiagnosed and untreated airflow limitation compatible with COPD.
Answers are grounded in this paper and cite their sources.
May support COPD screening in ischemic heart disease; hypothesis-generating for treatment effects on outcomes.
Airflow limitation compatible with chronic obstructive pulmonary disease affects almost one-third of patients with ischemic heart disease. Although airflow limitation is associated with additional morbidity and societal burden, it is largely undiagnosed and untreated. Clinical trial registered with www.clinicaltrials.gov (NCT 01485159).
No takes yet. Share an insight, caveat, or question.
Franssen et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: